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Background: Compared to American Whites, African Americans have a higher prevalence of type 2 diabetes
mellitus (T2DM), experiencing poorer metabolic control and greater risks for complications and death. Patient-level
factors, such as diabetes knowledge, self-management skills, empowerment, and perceived control, account
for >90% of the variance observed in outcomes between these racial groups. There is strong evidence that
self-management interventions that include telephone-delivered diabetes education and skills training are
effective at improving metabolic control in diabetes. Web-based home telemonitoring systems in conjunction
with active care management are also effective ways to lower glycosylated hemoglobin A1c values when
compared to standard care, and provide feedback to patients; however, there are no studies in African Americans
with poorly controlled T2DM that examine the use of technology-based feedback to tailor or augment diabetes
education and skills training. This study provides a unique opportunity to address this gap in the literature.
Methods: We describe an ongoing 4-year randomized clinical trial, which will test the efficacy of a technology-
intensified diabetes education and skills training (TIDES) intervention in African Americans with poorly controlled
T2DM. Two hundred male and female AfricanAmerican participants, 21 years of age or older and with a
glycosylated hemoglobin A1c level ≥8%, will be randomized into one of two groups for 12 weeks of telephone
interventions: (1) TIDES intervention group or (2) a usual-care group. Participants will be followed for 12 months
to ascertain the effect of the interventions on glycemic control. Our primary hypothesis is that, among African
Americans with poorly controlled T2DM, patients randomized to the TIDES intervention will have significantly
greater reduction in glycosylated hemoglobin A1c at 12 months of follow-up compared to the usual-care group.
Discussion: Results from this study will add to the current literature examining how best to deliver diabetes
education and skills training and provide important insight into effective strategies to improve metabolic control
and hence reduce diabetes complications and mortality rates in African Americans with poorly controlled T2DM.
Trial registration: This study was registered with the National Institutes of Health Clinical Trials Registry on 13
March 2014 (ClinicalTrials.gov identifier# NCT02088658).
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Diabetes mellitus affects approximately 29 million adults
in the United States [1]. African Americans (AAs) have a
higher prevalence of type 2 diabetes mellitus (T2DM),
poorer metabolic control and greater risk for complica-
tions and death compared to White Americans [2].
There is strong evidence that self-management interven-
tions that include diabetes education and skills training
are effective at improving metabolic control in diabetes
[3]. Recent findings indicate that patients with diabetes,
especially ethnic minority patients, prefer telephone-
delivered diabetes education to group visits or internet-
based education [4]. Multiple randomized controlled
trials have documented the effectiveness of telephone-
delivered self-care interventions in T2DM [5-8]. Prelim-
inary data from our group suggest that a culturally
tailored telephone-delivered diabetes education and skills
training intervention [9] is an effective strategy to improve
metabolic control in AA patients with T2DM.
Use of telephone contact, video-conferencing, personal
digital assistants and web-based systems offer new op-
portunities to bridge the gap in support for patients with
diabetes between face-to-face visits with their healthcare
providers. Three large-scale randomized controlled stu-
dies have shown that home telemonitoring in conjunc-
tion with active care management resulted in lower
glycosylated hemoglobin A1c (HbA1c) values at follow-
up when compared to standard care [8,10,11].
The FORA system (Fora Care Inc. 893 Patriot Drive,
Suite D, Moorpark, CA 93021, USA) is an inexpensive, off-
the-shelf, state-of-the-art technology whereby a person/
caregiver and a provider can communicate accurately on
data needed for self-management of diabetes. The system is
comprised of an easy to operate two-in-one blood glucose
and blood pressure monitor (Figures 1 and 2) that uploadsFigure 1 The FORA TeleHealth System. GSM, Global System for Mobile cresults to a secure website via a modem. The system pro-
vides an easy-to-use operation for users to accomplish two
important tests. The measured results can be uploaded to a
personal computer or web-based software by using a
RS232 cable via a communication device to connect the
FORA glucose monitor and web-based FORA TeleHealth
System using a phone modem (Figure 3). The provider (in
this case a nurse case manager (NCM) or diabetes educator
(DE)) can review the glucose and blood pressure readings
weekly and use the data to tailor diabetes education and
self-care skills training using motivational enhancement
techniques to achieve optimal metabolic control.
This paper describes the rationale, study aims and ob-
jectives, and research design and methods of an ongoing
4-year, randomized clinical trial to test the efficacy of a
technology-intensified diabetes education/skills training
(TIDES) intervention in AAs with poorly controlled
T2DM. The long-term goal of the project is to identify
effective strategies to improve metabolic control and
hence reduce diabetes complication and mortality rates
in AAs with T2DM.
Rationale
AAs have a higher prevalence of T2DM, poorer metabolic
control (that is, poorer blood glucose, blood pressure, and
lipid control), and greater risk for complications and death
compared to White Americans [2]. HbA1c is the primary
marker for glycemic control and is a strong independent
predictor of developing complications and increasing mor-
tality in T2DM [12]. Key self-care behaviors that influence
glycemic control (and HbA1c) include diet, physical activ-
ity, self-monitoring of blood glucose and medication ad-
herence [12].
No large randomized controlled trial has tested whether
providing feedback to patients using novel technologyommunications.
Key Features - D20  2-in-1
 Audible test results: English & Spanish
 2-in1 Funcon: Blood glucose & blood pressure
 Blood sample size 0.7 ul
 Test results in 7 seconds
 No-Coding
 Upper arm cuﬀ
 PC Link – Connect to Fora Telehealth server 
 Memory capacity – 450 readings 
Figure 2 The FORA two-in-one blood glucose and blood pressure device (D20).
Figure 3 Installation instructions for the FORA TeleHealth gateway.
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cemic and blood pressure control or whether using the
feedback to tailor and augment diabetes education and
skills training are effective at improving metabolic control.
More importantly, there are no studies in AAs with poorly
controlled T2DM that examine the use of technology-
based feedback to tailor and/or augment diabetes edu-
cation and skills training (that is, TIDES). This study
provides a unique opportunity to address this gap in the
literature.
Study aim and objectives
The primary aim of this study is to test the efficacy of a
TIDES intervention using the FORA two-in-one and Tele-
Health System for diabetes in improving HbA1c levels in
AAs with poorly controlled T2DM. The primary outcome
is HbA1c at 12 months post-randomization, while the sec-
ondary outcomes are blood pressure (BP) control, quality
of life (QoL), and resource utilization/cost at 12 months
post-randomization.
Methods
The study, which was funded in May 2013 and has
an anticipated closure date of April 2017, is an ongoing,
4-year, two-group randomized controlled trial with
randomization of individual participants, blinded out-
comes assessments at baseline, 3, 6, 9, and 12 months,
and concurrent economic evaluation.
Location and setting
The study sites for this study include the general internal
medicine, endocrine, family medicine, and community
care clinics affiliated with the Medical University of
South Carolina in Charleston, SC, USA.
Ethics and trial registration
The study is funded by grant R01DK098529 from the
National Institute of Diabetes and Digestive and Kidney
Diseases. The trial is approved by the Institutional Review
Board (IRB) of the Medical University of South Carolina
(Pro#00015064; IRB approval date: 17 January 2012). The
trial is registered (registration date, 13 March 2014) on the
United States National Institutes of Health Clinical Trials
Registry (ClinicalTrials.gov identifier# NCT02088658),
available online at: http://clinicaltrials.gov/ct2/show/
NCT02088658.
Trial population and recruitment
A total of 200 AAs with T2DM will be randomized to one
of two groups: 1) TIDES intervention group, which con-
sists of telephone-delivered diabetes knowledge/informa-
tion and skills; and 2) usual care.
We use two complementary approaches to identify
eligible study participants. The first method consists ofsystematic identification of AA patients with T2DM.
After obtaining approval for a partial waiver of the
Health Insurance Portability and Accountability Act
from our local IRB, we use clinic billing records over the
previous 12-month period to identify AA patients with
International Classification of Diseases, 9th revision,
codes consistent with a diagnosis of T2DM. The physi-
cians of eligible patients are notified of their patients’
potential eligibility and asked permission to enroll their
patients in this study. After consent is obtained from the
physicians, letters of invitation on clinic letterhead
signed by the patient’s physician are mailed to patients
from the study clinics. The letter provides information
about the study, explains the study requirements, and
clarifies that only patients who meet certain criteria are
eligible to participate in the study. The letter includes an
addressed and stamped postcard that patients can mail
back to indicate interest or lack of interest in participat-
ing in the study. In addition, the letter provides a tele-
phone number that interested patients can call to
receive detailed information about the study. In the let-
ter, patients are also informed that they will receive a
follow-up call in 2 weeks unless they mail back the post-
card or call to decline being contacted. Patients who
mail back the postcard and express interest or call the
provided telephone number receive detailed information
about the study. Patients who agree to participate are
asked to provide written consent and are scheduled for
the initial screening assessment.
The second method consists of referrals from physi-
cians, other clinic staff such as nurses, or patients them-
selves in response to recruitment flyers for the study.
The Principal Investigator shares the goals of the study
and inclusion/exclusion criteria with physicians and
clinic staff during clinic administrative meetings. Phy-
sicians and clinic staff are asked to refer appropriate
patients to the study research assistants. In addition,
IRB-approved recruitment flyers are posted in promin-
ent locations in the study clinics.
Regardless of the recruitment pathway, research staff
members obtain written informed consent, complete
screening for eligibility, and assure that participants
meet criteria for inclusion and participation in the study.
The procedure and risks are explained to the patients
and the consent form signed as per standard clinical
practice. Participants who meet eligibility criteria then
complete the remainder of the assessment battery.
Randomization
All participants are randomly assigned to one of the two
study arms (n = 100 per arm). The study coordinator
verifies all eligibility criteria prior to randomization. A
permuted block randomization method is used to assign
participants to one of the two groups: (a) TIDES
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minimize the likelihood that the blind will be broken.
The randomization is stratified by baseline HbA1c
levels (8 to 10% versus >10%). Using Research Elec-
tronic Data Capture, research assistants collect eligi-
bility information and enter the information into the
study database via the secured study website [13]. Once
eligibility is confirmed, the computer generates the
intervention assignment based on the pre-programmed
randomization scheme. All participants who are ran-
domized are entered into the study database and ana-
lyzed according to Consolidated Standards of Reporting
Trials guidelines [14].Intervention and control groups
There is one active treatment group (combined telephone-
delivered diabetes knowledge/information and telephone-
delivered motivation/behavioral skills training) and a
usual-care group.Description of the technology-intensified diabetes
education/skills training intervention
The intervention is based on the information-
motivation-behavioral skills model [15] and provides in-
formation, motivation, and behavioral skills training
(using motivational enhancement techniques). Patients
are assigned the FORA two-in-one TeleHealth System
and provided with glucose test strips to allow testing at
least once a day. They are asked to perform glucose
testing and blood pressure measurement using the
FORA system once daily. They are asked to upload the
measurements daily as soon as possible after the test is
performed. The NCMs or DEs have access to a secure
server to which the uploaded measurements are stored
in real time. The glucose and BP readings are used to
tailor and reinforce behavior change during weekly
telephone-delivered diabetes education sessions. The
TIDES intervention in essence facilitates increased fre-
quency of self-monitoring and titration of skills training
(that is, glucose testing, diet, physical activity, and
medication adherence) in response to test values to
optimize diabetes and blood pressure control. Parti-
cipants randomized to this group receive: 1) the FORA
system for self-monitoring; 2) weekly telephone-delivered
diabetes education/skills training; 3) patient activation (list
of five questions to ask their provider at every visit and
training on how to ask the questions); and 4) patient
empowerment (diabetes responsibility contracts, personal
goals, and flow charts for patients to record laboratory
results/medications and training on how to use the em-
powerment tools). The intervention is delivered by tele-
phone once a week for 12 weeks with each session lasting
approximately 30 minutes.Description of the usual-care group
Apart from study visits, patients randomized to the usual-
care group are followed by their primary-care providers.
The provider is responsible for determining treatment pa-
rameters, making changes in the treatment regimen, and
determining the timing of follow-up visits. Between sched-
uled office encounters, contact between patient and pro-
vider is patient initiated. The provider may use clinic
nurses to follow-up on problematic patients or patients
with abnormal results. In essence, this group receives the
current standard of care at the study clinics.
Content of individual treatment sessions for the TIDES
group
Session 1
After enrollment, randomization, and completing the
baseline assessment, each participant in the TIDES
group comes in for a face-to-face meeting with the
NCMs or DEs. The primary purpose of the face-to-face
visit is to establish rapport and give participants an op-
portunity to meet their NCM or DE. In addition, during
this visit, the NCM or DE goes over the study in detail,
obtains patient contact information, primary and alter-
nate telephone numbers, and establishes guidelines for
follow-up calls. In addition, participants receive informa-
tion specific to the group as described below.
Sessions 2–13
Participants randomized to the TIDES group receive the
culturally tailored education booklet that was developed as
part of Racial and Ethnic Approaches to Community
Health 2010 titled “Your Guide to Sugar Diabetes”. They
are trained on how to use the five patient activation ques-
tions during clinic visits. They are also given a patient
empowerment package and trained on how to use the ma-
terials in a diabetes care package. In addition, the NCM/DE
goes over the principles of behavioral skills training, asks
the participant to choose the first target behavior, and as-
sists the participant in developing an action plan.
The intervention group receives weekly telephone-
delivered diabetes knowledge/information, patient activa-
tion, patient empowerment, and behavioral skills training
delivered via telephone. Telephone sessions (2–13) for the
intervention group are delivered weekly for 12 weeks and
last for 30 minutes. Participants randomized to this group
participate in discussions on diabetes-related topics and
receive motivation/skills training in self-blood sugar moni-
toring, medication adherence, diet, and physical activity.
During the final week of discussion, a review of the major
points of each session covered previously is conducted.
Sessions 14–15
Treatment group-specific booster sessions for the TIDES
group are delivered by telephone at 6 and 9 months
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each session covered previously is conducted during the
booster sessions.Study instruments and data collection schedule
See Figure 4 and Tables 1, 2, 3 for the study design and study
flow, data collection schedule, data collection measures, and
data collection instruments, respectively.Figure 4 Design and study flow.Primary outcome measure
The primary outcome is HbA1c level at 12 months of
follow-up.
Sample size determination and power analysis
For the primary and secondary efficacy outcomes,
HbA1c (primary outcome) and BP, QoL, and resource
utilization/cost (secondary outcomes), with 80 subjects
randomized to each of the two groups, we have 85%
power to detect at least a 0.4 standardized effect size
(difference in comparison group means in standard devi-
ation (SD) units) for continuous outcome measures. This
calculation assumes that: the primary and secondary effi-
cacy outcomes are measured at five time points (base-
line, 3, 6, 9, and 12 months); the intra-class correlation
for repeated observations is no greater than 0.7; the level
of significance (α) = 0.05, two-tailed test. Assuming
HbA1c, systolic BP, and diastolic BP measurements have
standard deviations of approximately 2.0. 20.6, and 9.6,
respectively, based on our pilot studies, the study has
85% power to detect a difference of 0.8 percentage
points (raw units) in HbA1c, 8.2 mmHg in systolic BP,
and 3.8 mmHg in diastolic BP between the two compari-
son groups. Analyses for continuous QoL, process and
behavioral variables also have 85% power to detect a
standardized effect size of 0.4 SD. To account for the
“fraction of missing” information that must be imputed
in the intent-to-treat (ITT) sample and the dilution ef-
fect of ITT analyses [30], the sample size is inflated by
20% to achieve a final ITT sample size of 100 subjects
randomized to each treatment group (N = 200).
Data analysis
Primary hypotheses
Among AAs with poorly controlled T2DM, patients ran-
domized to the TIDES intervention will have signifi-
cantly greater reduction in HbA1c at 12 months of
follow-up compared to usual care.
The ITT sample, comprising all randomized patients,
will be used for the primary analyses [14]. The per
protocol/completer sample will comprise participants
who were compliant with protocol requirements and for
whom all required measurements over 12 months of
follow-up have been made. Analyses will be carried out
separately for ITT and per protocol samples to test sen-
sitivity of conclusions to drop-outs/non-adherence. If
differences are present between the per protocol and
ITT analysis sets, the characteristics of the two analysis
populations will be examined to aid in explaining any
discrepancies.
For primary analyses of longitudinal data, we will em-
ploy longitudinal data methods (mixed effects models)
which allow for missing data [32]. In addition, we will
model the dichotomous outcome, missing/not missing
Table 1 Data collection schedule













Glycosylated hemoglobin A1c X X X X X
Secondary outcome measures
Blood pressure X X X X X
Quality of life (12-item Short-Form Health Survey; SF-12) X X X X X
Resource utilization/cost X X X X X
Process measures
Diabetes knowledge questionnaire X X X X X
Knowledge about diabetes (The Diabetes Study of Northern California survey;
DISTANCE)
X X X X X
Diabetes education (Behavioral Risk Factor Surveillance System; BRFSS) X X X X X
Diabetes empowerment scale X X X X X
Behavioral skills (Summary of Diabetes Self-Care Activities; SDSCA) X X X X X
Medication adherence X X X X X
Diabetes fatalism X X X X X
Covariates/self-report measures
Patient demographics X
Social support X X X
Health literacy X X X
Depression (Patient Health Questionnaire-9; PHQ-9) X X X
Diabetes distress (Diabetes Distress Scale; DDS-2) X X X
Delayed discounting (Quick Delay Questionnaire; QDQ) X X X
Medical comorbidity (chronic health conditions, BRFSS) X X X
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if missingness is related to intervention group and/or ini-
tial level of the given outcome variable (baseline score).
Missing covariate data will be imputed using the multiple
imputation method of Little and Rubin [33] if needed.
We specify a priori the primary (HbA1c) and secondary
(BP and QoL) measures corresponding to a priori hypoth-
eses, and therefore maintain the significance level (alpha)
at 0.05 for these analyses, with no correction for multiple











Blood pressure readings will be o
assistant using automated blood
seated comfortably for 5 minutes
Quality of life The 12-item Short Form Health S
status and will be used to assess




The perspective of cost will be th
be administered as part of the baoutcomes, process measures) are considered secondary/
exploratory. We will carry out both unadjusted and
multiplicity-adjusted (using a Bonferroni-type correction)
analyses involving these variables, and will report both un-
adjusted and adjusted P-values in the event that conclu-
sions differ based on adjustment.
Discussion
The proposed study provides a unique opportunity
to address existing gaps in the literature by testing aat baseline, and at 3, 6, 9, and 12 months.
btained at baseline and at 3, 6, 9, and 12 months by a trained research
pressure monitors (OMRON IntelliSense™ HEM-907XL) with the patient
prior to the measurements.
urvey (SF-12) [16] is a valid and reliable instrument to measure functional
quality of life at baseline and at 3, 6, 9, and 12 months. The SF-12 items
riance in Physical Component Summary-36 and Mental Component
at of the payer. Previously validated questions on resource utilization will
seline and at 3, 6, 9, and 12 months.
Table 3 Data collection instruments
Measure Data collected Method
Process and behavioral
measures
Information This will be measured by the 24-item Diabetes Knowledge Questionnaire (DKQ) [17].
Knowledge about
diabetes
Previously validated items from the Diabetes Study of Northern California (DISTANCE) survey [18]
will be used to capture knowledge about diabetes.
Diabetes education Three previously validated items from the Behavioral Risk Factor Surveillance System (BRFSS) [19]
will be used to capture the patients’ confidence in diabetes self-management.
Motivation This will be measured by the eight-item Diabetes Empowerment Scale-Short Form (DES-SF) [20].
Self-efficacy This will be measured by the Perceived Diabetes Self-Management Scale (PDSMS) [21].
Behavioral skills This will be assessed with the Summary of Diabetes Self-Care Activities (SDSCA) scale [22].
Medication
adherence
This will be measured with the new eight-item self-report Morisky Medication Adherence Scale
(MMAS) [23].
Diabetes fatalism This will be measured with the 12-item Diabetes Fatalism Scales (DFS) [24], a valid and reliable measure
of diabetes fatalism that is associated with self-care problems, poor glycemic control, and decreased
quality of life.
Covariates Demographics Previously validated items from the 2002 National Health Interview Survey [25] will be used to capture
age, gender, race/ethnicity, marital status, household income, and health insurance.
Social support The Medical Outcomes Study (MOS) Social Support Survey [26] will be used to measure social support.
Health literacy The abbreviated version of the Test of Functional Health Literacy in Adults (S-TOFHLA) [27] is designed
to rapidly screen patients for potential health literacy problems.
Depression The Patient Health Questionnaire-9 (PHQ-9) is a brief questionnaire that scores each of the nine
Diagnostic and Statistical Manual of Mental Disorders (4th revision) criteria for depression [28].
Diabetes distress The Diabetes Distress Scale (DDS) is a two-item scale that measures patient concerns about disease
management, support, and emotional burden [29].
Delayed
discounting
The Quick Delay Questionnaire (QDQ) Discounting Module is a 10-item survey used to help researchers
understand how the amount of monetary gain and timing are associated with treatment adherence
and clinical outcomes among individuals with type 2 diabetes [30].
Medical
comorbidity
The patient's history of medical comorbidity will be documented using chronic health conditions
(previously validated items from the BRFSS) [31].
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information and motivation/behavioral skills training
intervention in AAs with poorly controlled T2DM. The
combined diabetes knowledge/information and motiv-
ation/behavioral skills intervention focuses on four key
behaviors (physical activity, diet, medication adherence,
and self-monitoring of blood glucose), maintains ad-
equate dose and intensity of the interventions by deliver-
ing the interventions weekly for 12 weeks, and allow
patients to choose one behavior to address every 3 weeks.
The findings of this study, if successful, will lead to the
implementation of this feasible, evidence-based interven-
tion for high-risk minority patients with T2DM. The study
findings will also provide new information on how to im-
prove quality of care for diabetes in ethnic minorities and
reduce the disproportionate burden of diabetes complica-
tions and deaths in ethnic minority groups with T2DM.
Trial status
The study was funded in May 2013. Study recruitment
began in December 2013, with all follow-up assessments
associated with the study expected to be completed by
April 2017. As of 30 October 2014, 295 patients have beenscheduled, 171 enrolled, and 106 randomized. Of the
number randomized, 24 have completed the 12-week
phone interventions, and 66 have completed the 3-month
follow-up assessment, 65 have completed the 6-month
follow-up assessment, and 23 have completed the 9-
month follow-up assessment.
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